DLBCL subtyping, FOXP1 expression determined by immunohistochemistry (IHC), and their relationship to FOXP1 isoforms identified by Western blotting
| DLBCL subtype by IHC, JC12 tumoral IHC . | Predominantly moderate to strong FOXP1 small isoforms . | Predominantly moderate to strong full-length FOXP1 . | Moderate to strong isoforms at equal levels . | Weak for either or both isoforms . | Negative for both isoforms . |
|---|---|---|---|---|---|
| NCG, n = 12 | |||||
| n = 5, + | 4 | 0 | 0 | 0 | 1 |
| n = 5, +/− | 0 | 0 | 1 | 3 | 1 |
| n = 2, − | 0 | 0 | 0 | 0 | 2 |
| n = 0, c | 0 | 0 | 0 | 0 | 0 |
| GC, n = 21 | |||||
| n = 9, + | 2 | 3 | 0 | 3 | 1 |
| n = 6, +/− | 1 | 0 | 0 | 2 | 3 |
| n = 4, − | 0 | 0 | 0 | 2 | 2 |
| n = 2, c | 0 | 0 | 0 | 0 | 2 |
| ?, n = 19 | |||||
| n = 7, + | 2 | 0 | 1 | 2 | 2 |
| n = 10, +/− | 1 | 0 | 0 | 5 | 4 |
| n = 2, − | 0 | 1 | 0 | 1 | 0 |
| n = 0, c | 0 | 0 | 0 | 0 | 0 |
| DLBCL subtype by IHC, JC12 tumoral IHC . | Predominantly moderate to strong FOXP1 small isoforms . | Predominantly moderate to strong full-length FOXP1 . | Moderate to strong isoforms at equal levels . | Weak for either or both isoforms . | Negative for both isoforms . |
|---|---|---|---|---|---|
| NCG, n = 12 | |||||
| n = 5, + | 4 | 0 | 0 | 0 | 1 |
| n = 5, +/− | 0 | 0 | 1 | 3 | 1 |
| n = 2, − | 0 | 0 | 0 | 0 | 2 |
| n = 0, c | 0 | 0 | 0 | 0 | 0 |
| GC, n = 21 | |||||
| n = 9, + | 2 | 3 | 0 | 3 | 1 |
| n = 6, +/− | 1 | 0 | 0 | 2 | 3 |
| n = 4, − | 0 | 0 | 0 | 2 | 2 |
| n = 2, c | 0 | 0 | 0 | 0 | 2 |
| ?, n = 19 | |||||
| n = 7, + | 2 | 0 | 1 | 2 | 2 |
| n = 10, +/− | 1 | 0 | 0 | 5 | 4 |
| n = 2, − | 0 | 1 | 0 | 1 | 0 |
| n = 0, c | 0 | 0 | 0 | 0 | 0 |
The intensity of tumoral FOXP1 expression was assessed by JC12 immunolabeling with −, +/−, +, and c reflecting negative, weak/moderate, strongly positive, and cytoplasmic labeling, respectively. The ? refers to cases for which subtyping data were not available.